Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

5th World Congress on Cancer Therapy

Atlanta, USA

Harrison R. Chuwa

Ocean Road Cancer Institute (ORCI), Tanzania

Title: Estimating the total cost of cancer management: A descriptive prospective Cohort study among patients with cervical cancer at Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Biography

Biography: Harrison R. Chuwa

Abstract

Background: Cervical cancer is the leading cancer in developing countries including Tanzania. In Tanzania, it is estimated that about 6,241 new cases of cervical cancer develop each year. ORCI is the only specialized centre for cancer treatment in Tanzania. Th e economic burden is important for policy formulation especially in Tanzania where cancer treatment is free. Aim: Th e objective of this study was to determine the actual cost of cancer treatment in Tanzania, with special emphasis on cervical cancer. Methods: Th e study was a descriptive prospective cohort design whereby both direct cost as well as indirect cost were determined using a standardized questionnaire for each patient of all new cervical cancer patients that were recruited in October, 2013 and followed up for a period of two months. Results: Th e overall cost per patient for cervical cancer ranged from USD 1, 257.24 to USD 3, 692.70 with the mean cost of USD 2, 452.45. Median direct cost was USD 2, 162.34 takes the largest share compared with the median indirect counterpart of USD 397.21. Th e mean direct cost for outpatients and inpatients was USD 1, 039.50 and USD 2, 301.75, respectively. Th e mean indirect cost for outpatients and hospitalized patients was USD 827.47 and USD 374.25, respectively. Conclusion: As in other studies, our fi ndings revealed that cervical cancer creates an immense fi nancial burden on patients and health care system. Primary prevention measures, vaccination against HPV and screening, should be initiated and expanded to reduce morbidity from cervical cancer and subsequent costs in both human lives and money resources.